The Boston-based synthetic biology firm said it will use the funds to grow its cell programing platform, which it will make available to startups.
The synthetic biology and DNA data storage firm will use the funds to launch its BioXp 3200 automated gene synthesis and cloning platform.
By acquiring Bothell, Washington-based Blue Heron, Eurofins Genomics could strengthen its offerings to the synthetic biology market.
The firm reported revenues of $13.6 million and raised full-year revenue guidance, but revised full-year earnings guidance downward.
The company is aiming to create a suite of products that can help researchers and manufacturers engineer various genomes at scale for multiple purposes.
The investment bank gave Danaher a Neutral rating and a $148 price target on the firm's shares, while it gave Agilent an Overweight rating with an $83 price target.
Evercore analysts set a price target of $30.50 for the company and said they see opportunities in DNA synthesis, NGS tools, pharmaceuticals, and DNA data storage.
In Nature this week: synthetic Escherichia coli genome with fewer codons, and more.
The company will offer 3.75 million shares of its common stock at $21 per share.
The company will use the proceeds to expand its R&D capabilities and its commercial operations.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.